Position in ABBV
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$3,732,324
+$647,881 QoQ
Shares Held
14,832
+4.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.50%
of 13F equity value
Holder Rank
#1,499
of 4,153 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026WILKINS INVESTMENT COUNSEL INC holds $77,139,543 across 7 Drug Manufacturers - General names. ABBV ranks #5 (4.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
244,471 | $31,414,523 | |
| 2 | NVS |
Novartis AG
|
111,067 | $17,406,420 | |
| 3 | JNJ |
Johnson & Johnson
|
66,797 | $16,964,434 | |
| 4 | PFE |
Pfizer Inc
|
176,761 | $4,256,404 | |
| 5 | ABBV |
AbbVie Inc.
This page
|
14,832 | $3,732,324 | |
| 6 | LLY |
ELI LILLY & Co
|
2,484 | $2,979,384 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
6,700 | $386,054 |
All Filings in ABBV
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,732,324 | 14,832 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $3,084,443 | 14,182 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $3,288,428 | 14,392 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $3,332,323 | 14,392 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $2,704,854 | 14,572 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $3,220,741 | 15,372 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $2,804,461 | 15,782 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $3,126,503 | 15,832 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $2,857,008 | 16,657 | Shares | Sole | 2024-08-08 | |
| 2024-03-31 | $3,069,659 | 16,857 | Shares | Sole | 2024-05-09 | |
| No filing history on record for this holder in this stock. | ||||||